Avascular necrosis, the death of bone tissue from loss of blood supply, is the most common bone complication of sickle cell disease and overwhelmingly targets the hip. Sickled red blood cells clog the tiny vessels feeding the femoral head, starving it of oxygen until sections of bone begin to collapse. The condition can develop in childhood and often affects both hips, eventually requiring joint replacement in many cases. Yet the interplay between genotype, early detection, and a widening range of treatments makes this a more layered problem than it first appears.
Why Sickle Cell Disease Destroys Bone
The femoral head sits at the top of the thighbone and fits into the hip socket. It depends on a limited network of blood vessels that leaves little room for backup circulation. In sickle cell disease, rigid crescent-shaped red blood cells obstruct these vessels, cutting off blood flow. When the bone loses its supply long enough, cells die and the bone weakens from within. Without intervention, the smooth spherical surface of the femoral head eventually crumbles, and the joint deteriorates.
The process is not purely mechanical. Research points to inflammatory and genetic factors that accelerate damage. Reduced levels of certain bioactive compounds in blood cells and elevated immune-signaling activity drive inflammation at the site of the blockage, compounding the ischemic injury already underway.1Europe PMC. An overview of pathophysiology and treatment options of osteonecrosis of femoral head in sickle cell disease This means the bone is getting hit from two directions at once: direct oxygen starvation and a sustained inflammatory assault that prevents repair.
Genotype and Who Faces the Highest Risk
Not everyone with sickle cell disease faces the same odds. A landmark study published in the New England Journal of Medicine tracked patients across different genotypes and found striking differences. Those with hemoglobin SS who also carried alpha-thalassemia had the highest rate of osteonecrosis, at roughly 4.5 cases per 100 patient-years. Patients with hemoglobin SS alone developed it at about 2.4 per 100 patient-years, while those with hemoglobin SC had a rate of about 1.9 per 100 patient-years.2PubMed. Sickle cell disease as a cause of osteonecrosis of the femoral head The SC group tended to develop the condition later in life, which matters for screening timelines. Intermediate rates were seen in patients with S-beta-zero thalassemia and S-beta-plus thalassemia genotypes.
The connection between alpha-thalassemia and higher risk may seem counterintuitive, because alpha-thalassemia generally makes sickle cell disease somewhat milder in other respects. But a separate study confirmed a significant positive correlation between alpha-gene deletion and both the prevalence and extent of avascular necrosis.3PubMed. The prevalence of avascular necrosis in sickle cell anemia: correlation with alpha-thalassemia One explanation is that higher red blood cell counts associated with alpha-thalassemia increase blood viscosity in the narrow vessels feeding the femoral head, making blockages more likely even though the individual cells may sickle a bit less. This is one of those areas where the genetics work against expectations, and it means clinicians should not assume that a “milder” genotype protects against bone damage.
Where Avascular Necrosis Strikes
The hip is by far the most common site. In a multicentre study using patient-reported outcome measures, hip avascular necrosis was present in about 72% of affected patients, and three-quarters of those had it in both hips.4British Journal of Haematology. Long‐term outcomes of avascular necrosis in sickle cell disease using joint‐specific patient‐reported outcome measures: Results from a multicentre study Bilateral involvement is the norm rather than the exception, which complicates treatment planning because both joints may need attention in succession.
The shoulder is the second most common target, though far less frequent. The same study found shoulder involvement in about 6% of patients, with mild to moderate functional impairment reported on standardized outcome scores. Knees and ankles can also develop avascular necrosis in sickle cell disease, though the hip dominates the clinical picture and the research literature. If you have sickle cell disease and develop unexplained pain in any major joint, the possibility of bone death should be on the table, even outside the hip.
Catching It Early With MRI
Timing matters enormously with avascular necrosis. The earlier it is caught, the more options exist to preserve the joint. Unfortunately, plain X-rays are poor at detecting early-stage disease. A comparative study found that MRI detected early-stage lesions (Ficat-Arlet stage 1) in about 15.6% of patients, compared to just 6.2% by X-ray. In stage 2 disease, MRI picked up roughly 32% of cases versus about 18% on X-ray.5International Journal of Radiology Sciences. Advantage of magnetic resonance imaging over X-Ray in diagnosis and evaluation of avascular necrosis of femoral head in patients with sickle cell disease MRI can reveal bone marrow edema and a characteristic “double-line sign” indicating ongoing ischemic damage, neither of which show up on standard X-rays.
This detection gap becomes a real-world problem in healthcare settings where MRI is not readily available. In many parts of sub-Saharan Africa, where sickle cell disease is most prevalent, plain radiographs remain the primary imaging tool. A review of referral patterns at one centre found that about 67% of patients were only referred to an orthopedic surgeon after X-ray changes had already become evident, and only 20% of patients presented within six months of their first symptoms.6PubMed Central. An Overview of Avascular Necrosis of the Hip in Patients with Sickle Cell Disease A broader review of African healthcare settings found that 85% of cases were diagnosed at advanced stages (Ficat stage III or IV), with delays sometimes exceeding two decades, largely because of limited MRI access.7PubMed Central. Hip Osteonecrosis in sickle cell disease: Contemporary orthopaedic practice and outcomes across African healthcare settings By the time plain X-rays reveal obvious collapse, the window for joint-preserving treatment has often closed.
Can Hydroxyurea Prevent It?
Hydroxyurea is the most widely used disease-modifying drug for sickle cell disease. It works by boosting fetal hemoglobin production, which interferes with the sickling process. The question of whether it protects against avascular necrosis has been studied from multiple angles, and the findings lean positive.
A pediatric study using MRI surveillance found that the frequency and rate of progression of femoral head avascular necrosis in children on hydroxyurea was “much less than that previously reported” in untreated patients. The authors found no evidence that hydroxyurea increases risk and suggested it may prevent new lesions and slow the progression of existing ones.8PubMed. Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation A comparative study looking at hydroxyurea versus blood transfusion found that the overall incidence of avascular necrosis was about 28%, but the rate was significantly lower in the hydroxyurea group (about 16%) compared to the transfusion-only group (about 36%), with a relative risk suggesting hydroxyurea roughly halved the odds.9CHILD`S HEALTH. Incidence of avascular necrosis in patients with sickle cell anemia received hydroxyurea and blood transfusion: a comparative study
These are encouraging signals, though they do not amount to a guarantee. Some patients on hydroxyurea still develop avascular necrosis. The drug reduces sickling episodes broadly, and bone protection appears to be one downstream benefit rather than a targeted prevention strategy. Still, the evidence adds another reason to the already substantial case for hydroxyurea adherence in sickle cell disease.
Treatment for Early-Stage Disease
When avascular necrosis is caught before the femoral head has collapsed, the goal shifts to preserving the natural joint for as long as possible. The two main approaches in early disease are physical therapy and core decompression, a surgical procedure where a small channel is drilled into the femoral head to relieve internal pressure and encourage new blood vessel growth.
A randomized trial comparing physical therapy alone with core decompression plus physical therapy found, after a mean follow-up of three years, that physical therapy alone appeared to be as effective at improving hip function and postponing additional surgery.10PubMed. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease A Cochrane systematic review examining the same trial noted that the clinical improvement scores were similar in both groups, with no clear difference in major complications.11Cochrane Database of Systematic Reviews. Treatment for avascular necrosis of bone in people with sickle cell disease
That said, a separate prospective case-control study painted a more favorable picture for core decompression, reporting significant pain reduction and functional improvement in 93% of operated hips. About 24% eventually progressed to total hip replacement, but the time to that point was significantly longer in the surgical group compared to those managed without the procedure.12PubMed. Treatment of sickle cell disease’s hip necrosis by core decompression: a prospective case-control study The discrepancy between studies is not unusual for a procedure being applied to a disease with highly variable progression. Core decompression may buy meaningful time for some patients, especially when the bone is still structurally intact, while doing relatively little for others.
Stem Cell and Bone Marrow Therapies
A more recent approach involves harvesting a patient’s own bone marrow cells and injecting them directly into the damaged femoral head during a minimally invasive procedure. The idea is that the concentrated stem and progenitor cells stimulate bone repair from within.
A five-year follow-up study in sickle cell patients who received this treatment reported significant pain relief as measured by standard hip scores, and about 96% of treated patients achieved a satisfactory clinical result. Radiographic assessment showed disease stabilization in most cases.13Stem Cell Research & Therapy. Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: a five-year follow-up study Another study in children with sickle cell disease found that about 88% of patients experienced complete pain relief after bone marrow cell implantation, while roughly 10% had significant improvement, and only one patient saw no benefit.14Frontiers in Cell and Developmental Biology. Therapy with bone marrow mesenchymal stem cells in bone regeneration in children with osteonecrosis secondary to sickle cell disease That study also found a significant link between younger age and better outcomes, reinforcing the case for early detection.
Earlier work on the same technique described it as “an effective alternative which preserves the native joint” and noted that joint replacement could be avoided in many patients when the procedure is performed in early-stage disease.15PubMed Central. Percutaneous implantation of autologous bone marrow osteoprogenitor cells as treatment of bone avascular necrosis related to sickle cell disease These results are promising, though the procedure is not yet widely available outside research centers, and long-term data beyond five years remain limited. The technique appears most effective for early-stage disease, which loops back to the same bottleneck: you need MRI screening to catch avascular necrosis before the bone has already collapsed.
Hyperbaric Oxygen as a Wild Card
Hyperbaric oxygen therapy, where a patient breathes pure oxygen in a pressurized chamber, has been explored as a treatment for avascular necrosis in sickle cell disease, though the evidence base is thin. A case report described a 15-year-old boy with sickle cell disease who had stage II avascular necrosis in both hips and one shoulder. After 57 sessions of hyperbaric oxygen, post-treatment MRI showed complete resolution of the necrosis in all three joints.16Frontiers in Medicine. Complete resolution of stage II avascular necrosis affecting three joints by hyperbaric oxygen in a patient with sickle cell disease: A case report That is a striking outcome in a single patient, and the authors themselves noted that using hyperbaric oxygen as a primary treatment for avascular necrosis in sickle cell disease “is not well evaluated yet.” For now, it remains an adjunctive option, not a standard one, but it is worth watching as more data accumulate.
When the Joint Cannot Be Saved
Total hip replacement becomes necessary when the femoral head has collapsed and conservative or joint-preserving measures are no longer viable. In the multicentre study mentioned earlier, about 59% of patients with hip avascular necrosis eventually underwent total hip arthroplasty, at a median age of roughly 35.17British Journal of Haematology. Long‐term outcomes of avascular necrosis in sickle cell disease using joint‐specific patient‐reported outcome measures: Results from a multicentre study That is decades younger than the average age of hip replacement in the general population, and the younger age brings its own challenges: the prosthesis must last through more years of use, and revision surgery becomes more likely over a lifetime.
Hip replacement in sickle cell disease carries higher complication rates than in other patient populations. A systematic review of 971 hip replacements in sickle cell patients found a revision rate of about 17%, with infections, loosening of the implant components, and intraoperative fractures all occurring at elevated rates. Sickle cell crises and transfusion reactions were the most common medical complications, reported in about 14% of cases. Intraoperative femoral fractures were especially common with uncemented prostheses.18PubMed Central. Total hip arthroplasty in sickle cell disease: a systematic review Despite these risks, all included studies demonstrated functional improvement, and outcomes have been getting better with improved patient selection and surgical technique.
A retrospective study reporting five-year follow-up found an overall survival rate of about 94%, with sickle cell crises during follow-up managed without catastrophe in most cases. Complications included superficial infections managed with antibiotics, one deep infection requiring a two-stage revision, and one case of aseptic stem loosening at seven years.19PubMed Central. Total Hip Replacement in Sickle Cell Disease Patients with Avascular Necrosis of Head of Femur: A Retrospective Observational Study The picture that emerges is that hip replacement works and restores function, but it demands careful perioperative management and honest conversations with patients about long-term risks.
Perioperative Considerations for Surgery
Surgery of any kind in sickle cell disease requires meticulous planning to avoid triggering a sickle cell crisis. Dehydration, low oxygen levels, cold temperatures, and stress can all provoke a crisis during or after an operation. Two general approaches to preoperative transfusion have been studied: an aggressive protocol aiming to bring hemoglobin S below 30% and a conservative protocol aiming simply to raise hemoglobin to about 10 g/dL.
One study comparing these approaches found that both could be used safely, but the aggressive protocol resulted in lower rates of postoperative complications, fewer additional transfusions, and less need for supplemental oxygen. No patient in the aggressive group experienced intraoperative blood loss exceeding 400 mL.20Journal of Orthopaedic Surgery. Perioperative Management for Orthopaedic Patients with Sickle Cell Anaemia A separate study from Martinique found that routine preoperative simple transfusion was warranted mainly when a patient was significantly below their steady-state hemoglobin, while exchange transfusion appeared to be associated with higher postoperative morbidity rates.21PubMed. Perioperative transfusion management in patients with sickle cell anaemia undergoing a total hip arthroplasty The transfusion strategy remains an active area of debate, and decisions tend to be individualized based on the patient’s baseline blood counts and the complexity of the planned procedure.
The Functional Toll Even After Treatment
One finding that does not get enough attention is that hip function remains impaired even after treatment. In the multicentre study using patient-reported outcome measures, hip scores revealed moderate to severe impairment both in patients who had undergone total hip replacement and in those who had not had surgery.22British Journal of Haematology. Long‐term outcomes of avascular necrosis in sickle cell disease using joint‐specific patient‐reported outcome measures: Results from a multicentre study That is a sobering result. It suggests that by the time most patients reach treatment, enough damage has accumulated that full restoration of function is unlikely, regardless of the path chosen. The disease itself, with its chronic pain, repeated crises, and effects on surrounding bone, creates a baseline of joint dysfunction that surgery can improve but rarely erase.
This finding reinforces the central frustration of avascular necrosis management in sickle cell disease: the outcomes depend heavily on catching the problem early, but the tools for early detection are not uniformly available, and the disease itself produces chronic pain that can mask the onset of a new problem in one specific joint. A patient who has lived with episodic bone pain for years may not immediately recognize that the pain in one hip has taken on a different character. Clinicians familiar with sickle cell disease know to ask, but the infrastructure for routine MRI screening of high-risk joints is not standard practice in most settings.